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Abstract Diagnosing a myelodysplastic syndrome (MDS)
can be challenging. Somatic mutations are common in
MDS and might have diagnostic utility in patients with
idiopathic cytopenias of undetermined significance
(ICUS). However, using mutations to diagnose MDS is
complicated by several issues: (1) no gene is mutated in
most cases, (2) no mutated gene is highly specific for
MDS, (3) clonal hematopoiesis is common in older indi-
viduals without disease, and (4) we lack outcome data for
ICUS patients with clonal cytopenias of undetermined
significance (CCUS). Despite these caveats, genetic se-
quencing can inform the diagnosis of MDS. CCUS pa-
tients more closely resemble patients with MDS than
age matched controls with somatic mutations. Genetic
testing can identify alternative diagnoses in cytopenic pa-
tients and help risk stratify those with proven MDS.
While we cannot include somatic mutations in the diag-
nostic definition of MDS now, testing to recognize CCUS
will help characterize outcomes in these diagnostically
challenging patients.
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Introduction
For several of reasons, myelodysplastic syndromes (MDS) are
often challenging to diagnose. MDS are heterogeneous disor-
ders that share key clinical features, including ineffective clon-
al hematopoiesis, morphologic dysplasia, peripheral blood cy-
topenias, and a variable risk of transformation to acute myeloid
leukemia (AML) [1]. However, clinical presentations can vary
dramatically from patient to patient. Establishing the diagnosis
of MDS requires the quantification of morphologic features
such as dysplasia and bone marrow blast proportion, both of
which are subject to interobserver variability even among ex-
pert hematopathologists [2, 3]. Diagnostic features ofMDS are
also frequently encountered in related disorders ranging from
aplastic anemia (AA) and myeloproliferative neoplasms
(MPN) to AML with myelodysplasia. Making an accurate di-
agnosis has important clinical consequences [4–6]. A more
objective mechanism for diagnosingMDS, particularly in con-
founding cases, would be of great clinical benefit [6–8].
Hematologists have long incorporated molecular genetic
information into the diagnostic evaluation of patients with
myeloid diseases. In chronic myelogenous leukemia (CML),
measurement of the leukocyte alkaline phosphatase has been
replaced by detection of the BCR-ABL fusion transcript—the
defining criterion for this disorder [9, 10]. Several subtypes of
AML are defined by the presence of specific chromosomal
translocations regardless of bone marrow blast proportion
[11]. And, in the10 years since the discovery of JAK2 muta-
tions in MPNs, these lesions can be diagnostic of polycythe-
mia vera (PV), essential thrombocythemia (ET), or primary
myelofibrosis (PMF) in the appropriate clinical contexts [12].
We have learned as much about the molecular genetic basis of
MDS in the last decade [13•]. There are well over 40 somat-
ically mutated genes seen recurrently in MDS, one or more of
which can be identified in over 90 % of patients [14••, 15••,
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16••].We understand howmutations are associated with many
disease features like ring sideroblasts, cytopenias,
monocytosis, and chromosomal abnormalities. The indepen-
dent prognostic value of many recurrently mutated genes has
been validated in numerous studies, and mutations that act as
biomarkers of response to specific therapies have been de-
scribed [17, 18, 19•, 20•]. Somatic mutations are not only
indicative of clonal hematopoiesis, a defining feature of
MDS, they identify the molecular drivers responsible for its
pathogenesis. These facts, and our experience with diagnostic
molecular tests in related myeloid disorders, suggest that mu-
tations could readily be incorporated into the diagnostic
criteria for MDS [21, 22].
Unfortunately, diagnostic utility of somatic mutations in
MDS is complicated by several issues. These include concerns
about poor specificity, the range of genetic variability present in
MDS, and a poor understanding about the implications of mu-
tations in patients who do not meet current diagnostic criteria.
This article will review current diagnostic methods forMDS and
will explore the role of molecular genetic testing in this context,
focusing on its challenges and how these may be overcome.
Section I—Current Diagnostic Criteria for MDS
Making a diagnosis of MDS appears fairly straightforward. A
patient must have at least one clinically meaningful cytopenia
and a bone marrow examination with one or more Bdecisive^
criteria for MDS (Table 1) [23]. However, meeting these
criteria is not sufficient until competing explanations for these
findings are excluded [11]. The list of benign conditions that
can mimic MDS or confound its diagnosis is long (Fig. 1).
Deficiencies of vitamin B12 or folate can cause cytopenias,
megaloblastic changes, and macrocytosis. Iron deficiency
can cause anemia and abnormal red cell morphology. Copper
deficiency, often seen in patients with gastric bypass or chron-
ic zinc ingestion, can result in anemia with ring sideroblasts, a
defining feature of some MDS subtypes. Viral infections can
cause bonemarrow suppressionwith dysplastic features as can
autoimmune conditions. These include Felty syndrome, idio-
pathic thrombocytopenia purpura, and systemic lupus erythe-
matosus among others.Medications taken to treat autoimmune
conditions, like methotrexate or azathioprine, can also cause
cytopenias and dysplasia. Chronic alcohol abuse can cause
morphologic dysplasia and cytopenias through a variety of
mechanisms such as liver damage, splenomegaly, and direct
bone marrow suppression. Then, there are several rare
inherited conditions that can mimic MDS, such as congenital
dyserythropoietic or sideroblastic anemias, which should be
considered, particularly in cases with a family history of ane-
mia. Finally, several clonal conditions that share clinical fea-
tures withMDS, including AML,MPN, and AA, must also be
excluded in order to make the diagnosis (Fig. 1).
The WHO guidelines recognize the challenge of diagnos-
ing patients with unexplained cytopenias, no increased blast
proportion, and a normal karyotype [11]. They recommend
Table 1 Diagnostic criteria for MDS and common findings
Peripheral blood findings Bone marrow findings Chromosomal abnormalities considered
presumptive evidence of disease
One or more of the following: And one or more of the following: Translocations:
Hemoglobin <11 g/dL ≥10 % dysplasia in the granulocytic,




<1500/μl (1.5 x 109/L)





<100,000/μl (100 x 109/L)
Presence of an acquired chromosomal
abnormality specific for MDS
t(1;3)(p36.3;q21.2)
t(6;9)(p23;q34)
Commonly observed features: Commonly observed features: Abnormal copy number:
Neutrophil hypogranularity Hypercellularity −7 or del(7q)
Hypolobulated neutrophil nuclei





Monocytosis (in CMML) Irregular nuclear contours −13 or del(13q)
Immature leukocytes Ring sideroblasts del(12p) or t(12p)
Macrocytosis Hypolobated megakaryocytes del(9q)
Anisopoikilocytosis Micromegakaryocytes del(11q)
Hypochromic erythrocytes Abnormal leukocyte granulation idic(X)(q13)
Large or hypogranular platelets Abnormal localization of immature precursors Complex karyotype
(3 or more abnormalities)Ectopic antigen expression by flow cytometry
Mild to moderate reticulin fibrosis
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that before making the diagnosis of MDS, patients with
unilineage dysplasia as their sole diagnostic finding demon-
strate 6 months of persistent cytopenia. Recovery of counts in
that time would suggest a cause other than MDS. The pres-
ence of an acquired chromosomal abnormality can be helpful
as it indicates clonal hematopoiesis. This does not exclude
benign causes of cytopenias but might make it more likely
that MDS or another clonal disorder is present. The WHO
guidelines include a list of chromosomal abnormalities that
can serve as presumptive evidence of the diagnosis, even in
the absence of dysplasia or increased blast proportion
(Table 1). These include several of the most frequent cytoge-
netic abnormalities seen in MDS such as del(5q), del(7q), loss
of chromosome 7, or a complex karyotype (defined as the
presence of three or more concurrent abnormalities). It is im-
portant to note that several recurrent chromosomal abnormal-
ities are not included in this list. Lesions such as del(20q) and
trisomy 8 are found in MDS but are present in many other
myeloid disorders and hence lack the necessary specificity
required to serve as diagnostic evidence of MDS. Loss of
chromosome Y is also not considered a diagnostic clonal
marker because it can frequently be seen in older men in the
absence of hematologic disease. In practice, less than 50 % of
patients with MDS will have an abnormal karyotype, and for
lower risk patients with no increasing in blasts, this fraction is
closer to 25 % [24, 25]. Cytopenic patients who do not reach
the arbitrary cutoffs of 10% dysplasia any lineage or 5% bone
marrow blast proportion will rarely carry a disease-defining
chromosomal abnormality. In contrast, somatic mutations in-
dicative of clonal hematopoiesis can be found in over 80 % of
MDS patients with lower risk disease [26]. This begs the
question of whether certain somatic mutations can substitute
for chromosomal abnormalities as presumptive evidence of
MDS in the absence of disease-defining morphologic criteria.
For reasons that are addressed below, the short answer to
this question at the moment is no. Somatic mutations should
not replace our current diagnostic standards for MDS as they
have for several myeloproliferative disorders.
Section II—Challenges to the Diagnostic Utility
of Somatic Mutation in MDS
To understand why somatic mutations are not reliably diag-
nostic ofMDS, it will be helpful to review the features of good
diagnostic biomarkers. The first is frequency. A mutation
present in the majority of cases of given disease is extremely
useful for its diagnosis. Even if the mutation occurs in other
disorders, the clinical context can help exclude these alterna-
tive diagnoses as unlikely. If a diagnosis is suspected on clin-
ical grounds but its highly frequent, associated mutation is
absent, the diagnosis must be considered much less likely or
ruled out altogether. This describes JAK2 mutations in the
diagnosis of PV. Even though JAK2 mutations can be found
in a variety of myeloid disorders, including MDS, a mutation
should be present in a patient clinically suspected of having
PV. If no JAK2 mutation can be identified after appropriate
testing, an alternative diagnosis such as secondary or congen-
ital polycythemia must be given greater weight as the diagno-
sis of PV is essentially excluded.
The second feature that can support the utility of a diagnos-
tic biomarker is specificity. A mutation uniquely associated
with a disease can be considered presumptive evidence of its
diagnosis. This is true even if the majority of the patients with
the disorder lack this particular mutation. Consider MPL mu-
tations which are present in 5 % of ET. While these mutations
are not present in the majority of ET patients, they are extreme-
ly rare in other conditions. Clinical context can exclude con-
founding conditions such as MF and refractory anemia with
ring sideroblasts (RARS) and thrombocytosis (RARS-T).
Therefore, a typical MPL mutation in a patient with isolated
thrombocytosis strongly supports the diagnosis of ET. Several
other MPN-associated gene mutations, such as those in CALR
for PMF and ET, KIT in mastocytosis, and the FIPL1-
PDGFRA rearrangement in the hypereosinophilic syndrome,
can also be considered specific enough for diagnostic use in the
appropriate clinical contexts. It is also helpful if the molecular
lesion in question is the founding abnormality that gives rise to
Fig. 1 Diagnostic overlap
between MDS and other clonal
disorders and benign conditions
that can mimic MDS. HIV human
immunodeficiency virus, EBV
Epstein-Barr virus, Hep hepatitis,
LGL large granular lymphocyte
leukemia
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the disease. This implies a degree of specificity but also en-
sures that the lesion will be present in the majority of clonal
cells making easier to detect. The BCR-ABL fusion gene in
CML is the classic example of causative, disease-defining mu-
tation that meets both the frequency and the specificity criteria
described above, making it an excellent diagnostic marker.
The examples above are MPNs where acquired mutations
are routinely incorporated into diagnostic criteria [11]. There
are several reasons why this is not yet the case for MDS. To
begin with, the clinical context for MDS is much more chal-
lenging to interpret than it is for MPNs. There are a limited
number ofmolecular mechanisms that causemyeloproliferation
and alternative diagnoses for patients with elevated cell counts
are few and relatively rare. In contrast, cytopenias and
myelodysplasia, the defining features of MDS, can be caused
by a broad array of molecular abnormalities and many potential
alternative causes of these findings are frequent. There is no
single gene that is mutated in the majority of cases of MDS.
Mutations of TET2 and SF3B1 are each present in only a quar-
ter to a third of patients [15••, 16••, 26]. A handful of other
genes (ASXL1, SRSF2, DNMT3A, and RUNX1) are mutated
in 10–20%, but the majority of recurrently mutated genes iden-
tified inMDS are present in fewer than 5% of cases. Therefore,
nomutated genemeets the frequency criteria that would allow a
diagnosis of MDS to be excluded if a particular mutation was
not identified.
Mutations could still be diagnostically useful if they were
highly specific for MDS. Unfortunately, this is not the case.
Like the del(20q) and trisomy 8 chromosomal abnormalities,
many genes mutated in MDS are observed in other myeloid
disorders where they have very different clinical implications.
For example, ASXL1 mutations are more common in chronic
myelomonocytic leukemia (CMML) than in MDS but can
also occur in MPN, AA, and AML [27–29]. Mutations of
TET2 and DNMT3A are found in these myeloid disorders
but can occur in lymphoid neoplasms as well [30].
Mutations of SF3B1 are the most specific as they are strongly
associated with the presence of ring sideroblasts, a readily
identifiable morphologic feature used to make the diagnosis
of MDS [31•]. However, SF3B1 mutations can also occur in
MPN/MDS overlap syndromes like CMML and RARS-T and
are frequent in CLL [32, 33].
Finally, there is a practical consideration that distinguishes
the mutations that support the diagnosis of MPN and AML
from the mutations most often seen in MDS. Many AML- or
MPN-related mutations are highly recurrent activating lesions
such as JAK2 V617F, the MPLW515L/K mutations, internal
tandem duplications of FLT3, or the frameshifts in the termi-
nal exons of CALR and NPM1. Most of the somatic mutations
in MDS are not so stereotypic. Genes can often be mutated
anywhere along their length and can harbor missense muta-
tions that can be difficult to distinguish from benign germline
polymorphisms or incidental passenger mutations unrelated to
the disease. This makes the interpretation of genetic tests more
difficult for many MDS-related genes given our current state
of knowledge.
Were these the only issues constraining the use of muta-
tions as diagnostic biomarkers for MDS, certain mutations in
specific genes might still have obvious diagnostic utility in the
appropriate clinical context. For example, if a patient with
ICUS (clinically significant cytopenias, morphologic criteria
for MDS not met, and no alternative diagnosis evident) were
found to have a typical mutation in DNMT3A, the presence of
clonal hematopoiesis would be established potentially making
a diagnosis of MDS more likely than a non-clonal cause of
their cytopenias. However, recent findings dictate caution in
making such an interpretation.
It is known that clonal hematopoiesis can occur in the ab-
sence of a clinically evident hematologic disorder. Studies of
skewed X chromosome inactivation demonstrate that some
women have clonal hematopoiesis and that this becomes in-
creasingly likely with age [34, 35]. More recent work has
confirmed that this is not a rare phenomenon [36]. In two
studies, subjects participating in genome-wide association
studies (GWAS) had their blood genotyped for single nucleo-
tide polymorphisms (SNPs) [37, 38]. This technique found
that 2–3 % of older participants carried chromosomal abnor-
malities likely to be acquired and therefore indicative of clonal
hematopoiesis. Two subsequent GWAS studies and a study of
patients with solid tumors examined the exomes of blood
samples from a total of over 30,000 individuals [39••, 40,
41••]. Likely somatic mutations in several MDS-associated
genes were found with a frequency that increased markedly
with age. Approximately 10 % of persons aged 70–80 carried
one or more of these mutations indicative of clonal hemato-
poiesis. The three most commonly mutated genes across these
studies were DNMT3A (accounting for more than half of all
cases), TET2, and ASXL1 which were closely followed by
mutations in JAK2, TP53, SF3B1, SRSF2, and CBL. Only
one frequently mutated gene, PPM1D, was not known to be
recurrently mutated in MDS [41••]. The median age of MDS
patients is in the 70–75 years range. The incidence of MDS in
this age group is several orders of magnitude lower that the
10 % rate of clonal hematopoiesis detected in this population.
More importantly, most of the individuals with clonal hema-
topoiesis had no known hematologic abnormality and there
was no association between the presence of somatic mutations
in these GWAS studies and clinically significant cytopenias.
The presence of a somatic mutation in these studies was not
clinically benign, however. Individuals with evidence of clon-
al hematopoiesis had a 10–15-fold increased risk of develop-
ing a hematologic malignancy, although not necessarily MDS
[39••, 41••]. This risk increased to 50-fold if the somatic mu-
tation was present in 20 % or more nucleated blood cells
(corresponding to a variant allele fraction of ≥0.10). Yet, the
absolute increase in risk remained very small, and the vast
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majority of patients with clonal hematopoiesis never went on
to develop a hematologic disorder. For this reason, incidental
findings of somatic mutations have been referred to as clonal
hematopoiesis of indeterminate potential, abbreviated as
CHIP [42••]. The high frequency of CHIP in the elderly pop-
ulation most likely to have MDS places strong constraints on
the diagnostic value of somatic mutations. The presence of a
DNMT3A, ASXL1, or TET2mutation typical ofMDS does not
clarify the diagnosis in an elderly cytopenic patient. Benign
causes of cytopenias and alternative clonal disorders would
still have to be excluded just as they would if these mutations
were not present.
Section III—Utility of DNA Sequencing at the Time
of Diagnosis
Given the many caveats discussed above, it may appear that
molecular genetic tests have no role in the diagnostic setting
for MDS. However, there are several scenarios in which so-
matic mutations can clarify the diagnosis and, in the future,
might inform a molecular definition of disease. CHIP was
described in various populations that were not suspected of
having a hematologic disorder. In practice, these are not the
people subjected to molecular genetic testing. Instead, it is the
cytopenic patients for which MDS is in the differential diag-
nosis that are more likely to undergo sequencing of their blood
or bone marrow. Finding a somatic mutation typical for MDS
in this clinical context may have different implications.
Currently, patients with unexplained cytopenias that do not
meet the diagnostic criteria for MDS are labeled as having
ICUS [7, 43•, 44]. The eventual outcome for patients with
ICUS is not well understood nor have clear risk features for
progressive disease been established. Small studies have sug-
gested that clonality may be one adverse risk factor [45].
Recent studies have demonstrated that a subset of ICUS pa-
tients carry somatic mutations in MDS-related genes indica-
tive of clonal hematopoiesis [46, 47]. This may not seem
surprising given the high rate of CHIP in the age range typical
for MDS. However, ICUS patients with clonal hematopoiesis,
henceforth referred to as having clonal cytopenias of undeter-
mined significance (CCUS), have other features that distin-
guish them from people with non-cytopenic CHIP [42••].
Two studies presented at the American Society of
Hematology Annual Meeting in 2014 examined diagnostic
material from cytopenic patients suspected of having
MDS. One was a prospective examination of 146 patients
[46]. Based on their bone marrow findings, 21 patients
were diagnosed with MDS, 22 as ICUS with some dysplas-
tic features not meeting criteria for MDS, and 103 as hav-
ing no morphologic features of MDS at all. A panel of 21
frequently mutated MDS genes was examined by next-
generation sequencing in each patient. In patients with a
clear diagnosis of MDS, 76 % had at least one typical
somatic mutation with more than a third having three or
more such mutations. The mutation rate was 55 % in the
ICUS group with some evidence of MDS and 22 % in
cytopenic patients with no evidence of MDS at all. The
fraction of CCUS patients across the two ICUS arms was
28 %, which is much higher than the 10–15 % of CHIP
expected in an aged matched Bnormal^ population.
Strikingly, the number of CCUS patient was nearly 1.5-
fold greater than the number of patients that met the diag-
nostic criteria for MDS, suggesting that the incidence of
CCUS may be large and comparable to that of MDS under
its current diagnostic definition.
The second study examined 250 sequential cases of ICUS
collected over 6 months at a commercial laboratory and com-
pared them to 90 cases of lower risk MDS diagnosed in the
same time frame [47]. The results were similar to the prior
study in that 33 % of ICUS patients carried at least one so-
matic mutation. In both studies, the genes mutated in ICUS
and MDS were similar with the exception of SF3B1 which
was rarely mutated in CCUS and common in MDS, particu-
larly lower risk MDS. Interestingly, the median variant allele
frequencies for MDS and CCUS were similar at about 30 %.
More than 80 % of mutations were present at an allele fre-
quency of at least 10 %, the median described for CHIP in
population studies. The likelihood of having clonal hemato-
poiesis in a cytopenic patient was greater than the background
rate of CHIP, and mutations were more abundant on average
suggesting a continuum between CHIP, CCUS, and MDS.
Unfortunately, we still lack data on outcomes in patients with
CCUS and how clinical and molecular features could help us
further refine disease risk in this group.
In absence of validated outcomes data, a Bayesian ap-
proach could help support the diagnosis of clinically mean-
ingful cytopenias even if they are not labeled as MDS. For
example, persons with CHIP were mostly over age 50 and
typically had one MDS-related mutation at a low (<10 %)
variant allele frequency. If a 45 year-old patient with ICUS
were found to carry two or more mutated genes with a variant
allele frequency of 30–40 %, it would seem much less likely
that this person had CHIP and coincidentally, an overlooked
benign cause for their cytopenias. Similarly, if a 73 year-old
cytopenic patient has no somatic mutations detected in a large
panel of genes, alternatives to MDS should be strongly
considered.
We may learn that certain mutations have different degrees
of diagnostic utility. For example, DNMT3A, TET2, and
ASXL1 are so frequent in CHIP and so prevalent in disorders
other thanMDS that an isolatedmutation in one of these genes
likely cannot be considered diagnostically helpful (Table 2).
Some of the less frequently mutated CHIP genes, likeU2AF1,
RUNX1, and TP53, may retain some specificity for MDS in
the appropriate clinical context.
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Several genes are mutated much more frequently in disor-
ders that can mimic MDS. For example, a BRAFmutation in a
cytopenic patient without marked dysplasia should prompt
careful examination for features of hairy cell leukemia, a rare
cause of cytopenias that nearly always carries an activating
BRAF mutation [48]. Similarly, recurrent mutations of
STAT3 and STAT5B have been associated with clonal large
granular lymphocyte leukemia, a disorder of T or NK cells
that can present like MDS, but is treated very differently [49,
50]. Just as t(8;21), inv(16), t(16;16), and t(15;17) define spe-
cific subtypes of AML regardless of bone marrow blast pro-
portion, there may be mutated genes that are de facto evidence
of leukemia. These might include small FLT3-ITD mutant
subclones or more abundant mutations of IDH1, IDH2, or
NPM1, all of which are very rare in both CHIP and MDS
compared with AML [51, 52].
Rare cytopenic patients may have germline mutations in
genes associated with an increased risk of developing MDS
or AML. The genes involved can include RUNX1, CEBPA,
GATA2, ETV6, DDX41, TERT, DKC1, and TP53, among
others [53–56]. Patients may have a suggestive family history,
earlier age at diagnosis, and clinical manifestations specific to
the congenital mutation involved. However, patients can pres-
ent later in life with bone marrow failure as their only prom-
inent clinical finding, and germline mutations can occur de
novo in individuals with no relevant family history [57, 58].
Often, patients may have a prodromal stage of abnormal blood
counts without clear evidence of MDS or AML. This is com-
mon in patients with germline RUNX1, ETV6, or GATA2 mu-
tations, for example [54, 55]. Genetic testing at diagnosis may
identify these individuals earlier in the course of disease and
help screen siblings if related donor allogeneic stem cell trans-
plant is being considered.
Finally, DNA sequencing at the time of diagnosis may
identify somatic mutations that help classify patients with tra-
ditionally defined MDS. Currently, only patients with isolated
del(5q) are classified based on a genetic abnormality. These
patients share a clinical phenotype including a more favorable
prognosis and a striking response to treatment with
lenalidomide [59]. However, there are likely similar pheno-
typic subtypes of MDS that might be defined by somatic mu-
tations. The most evident are those patients with SF3B1 mu-
tations who commonly have ring sideroblasts [31•, 60, 61]. In
the current schema, patients with >15 % ring sideroblasts,
<5 % myeloblasts, and isolated erythroid dysplasia are
assigned the RARS subtype. This threshold for ring
sideroblasts is arbitrarily defined and has no biologic signifi-
cance. It may be better to define a subtype based on SF3B1
mutation status independent of ring sideroblast percentage
[62]. Several studies suggest that this would create a more
uniform subset of patients [63, 64•]. On the other end of the
risk spectrum, patients with TP53 mutations may comprise
another MDS subtype. Patients with TP53 mutations have
fewer mutations in other genes and often carry multiple chro-
mosomal lesions that can include del(5q), monosomy 7, or an
abnormal chromosome 17 [14••, 19•, 20•, 65, 66]. Clinically,
these patients are more likely to have thrombocytopenia, ex-
cess bone marrow blasts, and shorter overall survival.
Mutations in other genes, or recurrent combinations of genes,
may define additional clinically significant MDS subtypes in
the future [15••, 16••].
Conclusion
Current evidence does not support the use of somatic muta-
tions as presumptive evidence of MDS absent traditional di-
agnostic criteria [42••]. However, genetic testing at the time of
initial evaluation can aid in establishing a diagnosis and can
provide additional clinically relevant information. In cases
that meet morphologic criteria for MDS, typical somatic mu-
tations strongly support the diagnosis. Several of these lesions
have demonstrated prognostic significance that can refine risk
stratification and impact treatment decisions. As with the
del(5q) chromosomal abnormality, some gene mutations
may be strongly associated with clinical features and thus be
used to help classify MDS subtypes in patients that meet the
classical diagnostic criteria.
In cytopenic cases that are diagnostically unclear, somatic
mutations must be interpreted more cautiously [8]. Genetic
mutations recurrently identified in MDS patients lack the fre-
quency and specificity required to serve as presumptive evi-
dence of the disease, particularly due to high rate of CHIP
defined by the same abnormalities in patients without a hema-
tologic disorder. Even in this setting, somatic mutations can be
useful. Finding more than one typical mutation at higher allele
frequencies may raise the likelihood that the mutations and
cytopenias are linked, particularly in younger patients where
the rate of incidental CHIP is low. Other mutations, if present,
may raise the likelihood of diagnoses other thanMDS or iden-
tify patients with a congenital mutation predisposing to MDS/
AML. And, the absence of mutations in a sufficiently broad
gene panel may identify patients with lower risk of progres-
sion or in which an eventual diagnosis of MDS is less likely.
The key to these approaches will be to start with a careful
appreciation of the clinical context. Low frequency somatic
mutations in patients with mild cytopenias and only marginal
suspicion for MDS should be given little significance. In fact,
these patients should likely not be tested for mutations at all.
Patients with more profound cytopenias in which alternative
diagnoses have been carefully explored may be more likely to
harbor clinical relevant mutations. These CCUS patients may
merit closer observation, or if severely affected, might be
treated similarly to patients with lower risk, transfusion depen-
dent MDS. As it stands today, there is insufficient evidence
regarding the long-term outcomes of patients with CCUS to
288 Curr Hematol Malig Rep (2015) 10:282–291
merit redefining the diagnostic criteria for MDS. With this in
mind, an added benefit of sequencing cytopenic patients at the
time of diagnosis is that it will allow us to recognize and study
CCUS patients longitudinally to determine the impact of mu-
tations on their eventual outcome.
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